Format

Send to

Choose Destination
Ann Oncol. 2015 May;26(5):829-32. doi: 10.1093/annonc/mdv154. Epub 2015 Mar 23.

An ESMO-EORTC position paper on the EU clinical trials regulation and EMA's transparency policy: making European research more competitive again.

Author information

1
European Society for Medical Oncology (ESMO), Lugano, Switzerland Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-LB Cluster Translational Oncology, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria christian.dittrich@wienkav.at.
2
European Organisation for Research and Treatment of Cancer (EORTC), Brussels International Regulatory and Intergroup Office, EORTC Headquarters, Brussels, Belgium.
3
European Society for Medical Oncology (ESMO), Lugano, Switzerland Department of Cancer Medicine, Istituto Nazionale Tumori, Milan, Italy.
PMID:
25802239
DOI:
10.1093/annonc/mdv154
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center